BioSpace News Archive

The Silverstein Foundation for Parkinson’s with GBA today announced grant funding to AcureX Therapeutics to support the development of novel, first in class, small molecule drug candidates for the treatment of Parkinson’s disease (PD).

Genetic Technologies Limited is pleased to provide the financial results for the year ended June 30, 2021.

Today BIOLASE announced a clinical advisory partnership with Dr. L. Stephen Buchanan that will help expand laser adoption and increase hands-on training programs with one of the global leaders in endodontics.

ImmunoGenesis Inc.,announces the publication of positive data for its STimulator of INterferon Genes (STING) agonist in the treatment of canines with previously diagnosed glioblastoma (GBM), the second most common type of canine brain cancer that shares very close similarities to its human counterpart, in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Wells Fargo Healthcare Conference and participate in a fireside chat at the 2021 Morgan Stanley Global Healthcare Conference.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced four data presentations on the clinical value of mymobility® with Apple Watch®, a first-of-a-kind remote care management platform designed to help healthcare professionals remotely support and guide patients as they prepare for and recover from orthopedic procedures.

Jacobio Pharmaceuticals (“Jacobio”, 1167.HK) announced a strategic investment in the US-based biotech company Hebecell on August 31 .

Scientists at Children’s Hospital Los Angeles have been paying close attention to the behavior of SARS-CoV-2, since the beginning of the pandemi

New diagnoses of eight common types of cancer (prostate, breast, colorectal, lung, pancreatic, cervical, gastric and esophageal) significantly declined during most of the first 13 months of the pandemic (March 2020-March 2021), according to a Health Trends® study from Quest Diagnostics (NYSE: DGX) published today in JAMA Network Open.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against the Company.